Know Cancer

forgot password

A Phase II Trial of ZD1839 (Iressa) (NSC# 715055) in the Treatment of Persistent or Recurrent Epithelial Ovarian or Primary Peritoneal Carcinoma

Phase 2
Not Enrolling
Ovarian Cancer, Primary Peritoneal Cavity Cancer

Thank you

Trial Information

A Phase II Trial of ZD1839 (Iressa) (NSC# 715055) in the Treatment of Persistent or Recurrent Epithelial Ovarian or Primary Peritoneal Carcinoma


- Determine the antitumor cytostatic activity of gefitinib, in terms of 6-month
progression-free survival, in patients with persistent or recurrent ovarian epithelial
or primary peritoneal carcinoma.

- Determine the nature and degree of toxicity in patients treated with this drug.

- Determine the partial and complete response rates in patients treated with this drug.

- Determine the duration of progression-free and overall survival in patients treated
with this drug.

OUTLINE: This is a multicenter study.

Patients receive oral gefitinib once daily. Courses repeat every 28 days in the absence of
disease progression or unacceptable toxicity.

Patients are followed every 3 months for 2 years, every 6 months for 3 years, and then
annually thereafter.

PROJECTED ACCRUAL: Approximately 22-60 patients will be accrued for this study within 1-2

Inclusion Criteria


- Histologically confirmed ovarian epithelial or primary peritoneal carcinoma

- Recurrent or persistent disease

- Must have had prior therapy with no more than 1 platinum-based chemotherapy regimen
(e.g., carboplatin, cisplatin, or other organoplatinum compound) for primary disease

- Platinum-resistant or refractory

- Treatment-free interval of less than 6 months after therapy with
platinum-containing regimen OR

- Progression during platinum-containing regimen OR

- Platinum sensitive defined as treatment-free interval without disease
progression for more than 6 months but less than 12 months after therapy with
platinum-containing regimen

- At least 1 lesion measurable in at least 1 dimension

- At least 20 mm by conventional techniques (e.g., palpation, plain x-ray, CT
scan, or MRI) OR

- At least 10 mm by spiral CT scan

- At least 1 target lesion outside a previously irradiated field

- Disease must be accessible to core needle biopsy

- Ineligible for higher priority GOG protocol



- Not specified

Performance status:

- GOG 0-2

Life expectancy:

- Not specified


- Absolute neutrophil count at least 1,500/mm^3

- Platelet count at least 100,000/mm^3


- Bilirubin no greater than 1.5 times upper limit of normal (ULN)

- SGOT no greater than 2.5 times ULN

- Alkaline phosphatase no greater than 2.5 times ULN


- Creatinine no greater than 1.5 times ULN


- No unstable cardiac disease

- No myocardial infarction within the past 6 months

- Coronary artery disease, congestive heart failure, and dysrhythmia allowed if on
stable regimen for at least 3 months


- Not pregnant

- Negative pregnancy test

- Fertile patients must use effective contraception

- No sensory or motor neuropathy greater than grade 1

- No active corneal disease (e.g., keratoconjunctivitis)

- No active infection requiring antibiotics

- No evidence of bowel dysfunction that could be related to early bowel obstruction

- No other invasive malignancy within the past 5 years except nonmelanoma skin cancer


Biologic therapy:

- At least 3 weeks since prior immunological agents for the malignancy

- No concurrent anti-cancer immunotherapy


- See Disease Characteristics

- No more than 1 additional prior cytotoxic chemotherapy regimen for recurrent or
persistent disease

- No prior noncytotoxic chemotherapy for recurrent or persistent disease

- At least 3 weeks since prior chemotherapy for the malignancy and recovered

- No concurrent anti-cancer chemotherapy

Endocrine therapy:

- At least 1 week since prior anticancer hormonal therapy

- Concurrent hormone replacement therapy allowed

- No concurrent anti-cancer hormonal therapy


- See Disease Characteristics

- At least 3 weeks since prior radiotherapy for the malignancy and recovered

- No prior radiotherapy to more than 25% of marrow-bearing areas

- No concurrent anti-cancer radiotherapy


- At least 4 weeks since prior surgery (except minor procedures under local anesthesia
(e.g., central venous port placement)) and recovered


- At least 3 weeks since other prior therapy for the malignancy

- No prior gefitinib

- No other prior epidermal growth factor receptor inhibitors

- No prior anticancer therapy that would preclude study therapy

- No concurrent chlorpromazine

- No other concurrent investigational agents

- No other concurrent antineoplastic agents

- No concurrent CYP3A4-inducing agents, including phenytoin, carbamazepine,
barbiturates, nafcillin, rifampicin, or St. John's Wort

Type of Study:


Study Design:

Primary Purpose: Treatment

Principal Investigator

Russell J. Schilder, MD

Investigator Role:

Study Chair

Investigator Affiliation:

Fox Chase Cancer Center


United States: Federal Government

Study ID:




Start Date:

August 2001

Completion Date:

May 2006

Related Keywords:

  • Ovarian Cancer
  • Primary Peritoneal Cavity Cancer
  • recurrent ovarian epithelial cancer
  • primary peritoneal cavity cancer
  • Ovarian Neoplasms
  • Peritoneal Neoplasms
  • Neoplasms, Glandular and Epithelial



Roswell Park Cancer Institute Buffalo, New York  14263
Fred Hutchinson Cancer Research Center Seattle, Washington  98109
Memorial Sloan-Kettering Cancer Center New York, New York  10021
University of Texas - MD Anderson Cancer Center Houston, Texas  77030-4009
Mayo Clinic Cancer Center Rochester, Minnesota  55905
Jonsson Comprehensive Cancer Center, UCLA Los Angeles, California  90095-1781
Chao Family Comprehensive Cancer Center Orange, California  92868
University of Colorado Cancer Center Denver, Colorado  80262
Walter Reed Army Medical Center Washington, District of Columbia  20307-5000
H. Lee Moffitt Cancer Center and Research Institute Tampa, Florida  33612
Rush-Presbyterian-St. Luke's Medical Center Chicago, Illinois  60612
University of Chicago Cancer Research Center Chicago, Illinois  60637
Indiana University Cancer Center Indianapolis, Indiana  46202-5265
Albert B. Chandler Medical Center, University of Kentucky Lexington, Kentucky  40536-0084
University of Massachusetts Memorial Medical Center Worcester, Massachusetts  01655
Barbara Ann Karmanos Cancer Institute Detroit, Michigan  48201
University of Minnesota Cancer Center Minneapolis, Minnesota  55455
University of Mississippi Medical Center Jackson, Mississippi  39216-4505
Washington University School of Medicine Saint Louis, Missouri  63110
Cooper Hospital/University Medical Center Camden, New Jersey  08103
Cancer Center of Albany Medical Center Albany, New York  12208
State University of New York Health Science Center at Brooklyn Brooklyn, New York  11203
State University of New York Health Sciences Center - Stony Brook Stony Brook, New York  11790-7775
Lineberger Comprehensive Cancer Center, UNC Chapel Hill, North Carolina  27599-7295
Duke Comprehensive Cancer Center Durham, North Carolina  27710
Barrett Cancer Center, The University Hospital Cincinnati, Ohio  45219
Ireland Cancer Center Cleveland, Ohio  44106-5065
Arthur G. James Cancer Hospital - Ohio State University Columbus, Ohio  43210
University of Oklahoma College of Medicine Oklahoma City, Oklahoma  73190
Abington Memorial Hospital Abington, Pennsylvania  19001
Milton S. Hershey Medical Center Hershey, Pennsylvania  17033
Kimmel Cancer Center of Thomas Jefferson University - Philadelphia Philadelphia, Pennsylvania  19107
University of Pennsylvania Cancer Center Philadelphia, Pennsylvania  19104
Fox Chase Cancer Center Philadelphia, Pennsylvania  19111
Medical University of South Carolina Charleston, South Carolina  29425-0721
Simmons Cancer Center - Dallas Dallas, Texas  75235-9154
Tacoma General Hospital Tacoma, Washington  98405
Ellis Fischel Cancer Center - Columbia Columbia, Missouri  65203
University of Alabama at Birmingham Comprehensive Cancer Center Birmingham, Alabama  35294-3300
Community Hospital of Los Gatos Los Gatos, California  95032
Holden Comprehensive Cancer Center at The University of Iowa Iowa City, Iowa  52242-1009
Tufts University School of Medicine Boston, Massachusetts  02111
Comprehensive Cancer Center at Wake Forest University Winston-Salem, North Carolina  27157-1082
Brookview Research, Inc. Nashville, Tennessee  37203
Cancer Center at the University of Virginia Charlottesville, Virginia  22908
Cleveland Clinic Taussig Cancer Center Cleveland, Ohio  44195
Keesler Medical Center - Keesler AFB Keesler AFB, Mississippi  39534-2576
Schneider Children's Hospital at North Shore Manhasset, New York  11030
Fletcher Allen Health Care - Medical Center Campus Burlington, Vermont  05401
Medical Oncology Clinical Research Unit Bethesda, Maryland  20892